CURE EB (FORMERLY KNOWN AS SOHANA RESEARCH FUND)
SRF seeks to assist those suffering from Epidermolysis Bullosa ("EB"), in particular but not exclusively by making grants:(1) to fund medical research and/or clinical trials anywhere in the world for the purpose of discovering, developing and delivering treatments for EB; and(2) to fund the treatment of patients who are suffering from EB.
Objects
FOR THE PUBLIC BENEFIT, (A) THE ADVANCEMENT OF HEALTH AND (B) THE RELIEF AND ASSISTANCE OF PEOPLE IN NEED WHO ARE SUFFERING FROM EPIDERMOLYSIS BULLOSA, IN PARTICULAR BUT NOT EXCLUSIVELY BY MAKING GRANTS: (1) TO FUND MEDICAL RESEARCH AND/OR CLINICAL TRIALS ANYWHERE IN THE WORLD FOR THE PURPOSE OF DISCOVERING, DEVELOPING AND DELIVERING TREATMENTS FOR EPIDERMOLYSIS BULLOSA; AND (2) TO FUND THE TREATMENT OF PATIENTS WHO ARE SUFFERING FROM EPIDERMOLYSIS BULLOSA. NOTHING IN THIS CONSTITUTION SHALL AUTHORISE AN APPLICATION OF THE PROPERTY OF THE CIO FOR THE PURPOSES WHICH ARE NOT CHARITABLE IN ACCORDANCE WITH SECTION 7 OF THE CHARITIES AND TRUSTEE INVESTMENT (SCOTLAND) ACT 2005 OR SECTION 2 OF THE CHARITIES ACT (NORTHERN IRELAND) 2008.
Financial health, per its FY2025 accounts
The accounts state that Cure EB held unrestricted and restricted reserves of £7,381,688 at year-end, significantly exceeding its operating costs due to substantial donations. The charity reported a net movement in funds of £2,256,136, with gross income of £3,548,376 against charitable expenditure of £1,208,298. The trustees confirmed adequate resources to continue operations, noting that reserves substantially exceeded commitments.
What the accounts disclose
“In the year there were donations to the Charity from the Trustees amounting to £250,204 (2024: £1,247,865) (which are increased by Cure EB claiming Gift Aid).” — page 28
“During the year the Charity introduced £38,166 (2024: £638,664) of support to its subsidiary EB Therapeutics Ltd.” — page 28
“In the year there were donations to the Charity from the Trustees amounting to £250,204 (2024: £1,247,865) (which are increased by Cure EB claiming Gift Aid).” — page 28
“During the year the Charity introduced £38,166 (2024: £638,664) of support to its subsidiary EB Therapeutics Ltd.” — page 28
Policies the charity declares
- Complaints handling
- Complaints policy and procedures
- Conflicting interests
- Financial reserves policy and procedures
- Internal charity financial controls policy and procedures
- Investing charity funds policy and procedures
- Risk management
- Safeguarding policy and procedures
- Safeguarding vulnerable beneficiaries
- Trustee conflicts of interest policy and procedures
- Trustee expenses policy and procedures
From the charity’s annual return (Part A, self-declared)
Self-declared on the annual return for the financial year ending 31/12/2025
- Volunteers: 20
- Has a trading subsidiary
- Grant-making is its main activity
Self-declared on the annual return for the financial year ending 31/12/2024
- Volunteers: 15
- Has a trading subsidiary
- Grant-making is its main activity
Self-declared on the annual return for the financial year ending 31/12/2023
- Volunteers: 15
- Has a trading subsidiary
- Grant-making is its main activity
Leadership, per the charity’s website
- Sharmila — Founder and Trustee
Funders the charity credits
- Goldman Sachs Gives
- Redburn
Structured financials (annual return, FY ending 31/12/2025)
Register events
- Received assets from another charity (08/12/2021)
Trustees
- Duncan Wales
- JAMES DOUGLAS COLLINS
- MICHAEL GEORGES DE LATHAUWER
- PROFESSOR DAVID KELSELL
- Rachel Lesiter
- SHARMILA VIJAYANTHI NIKAPOTA
- TAZIM HALL
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/12/2025 | £3.5m | £1.3m |
| 31/12/2024 | £4.9m | £1.4m |
| 31/12/2023 | £731k | £1.6m |
| 31/12/2022 | £1.0m | £1.1m |
| 31/12/2021 | £1.6m | £859k |
Common questions
Is CURE EB (FORMERLY KNOWN AS SOHANA RESEARCH FUND) financially healthy?
Per its FY2025 accounts: The accounts state that Cure EB held unrestricted and restricted reserves of £7,381,688 at year-end, significantly exceeding its operating costs due to substantial donations. The charity reported a net movement in funds of £2,256,136, with gross income of £3,548,376 against charitable expenditure of £1,208,298. The trustees confirmed adequate resources to continue operations, noting that reserves substantially exceeded commitments. Its FY2025 accounts were audited by Mitchell Charlesworth (Audit) Limited.
Who funds CURE EB (FORMERLY KNOWN AS SOHANA RESEARCH FUND)?
Funders whose own accounts filings name CURE EB (FORMERLY KNOWN AS SOHANA RESEARCH FUND) as a grant recipient include THE REED FOUNDATION.
Known funders
| Funder | Year | Amount | Purpose (as stated by the funder) |
|---|---|---|---|
| THE REED FOUNDATION | FY2022 | £11k | Christmas Challenge |
| THE REED FOUNDATION | FY2021 | amount not stated |
Funders of similar charities
| Funder | Similar charities funded | Amount to them |
|---|---|---|
| THE PENNIES FOUNDATION | 1 | £44k |
| THE 29TH MAY 1961 CHARITY | 1 | £30k |
| BNA CHARITABLE INCORPORATED ORGANISATION | 1 | £25k |
| THE SYNCONA FOUNDATION | 1 | £20k |
| THE O'SULLIVAN FAMILY CHARITABLE TRUST | 1 | £16k |
| THE ROAN CHARITABLE TRUST | 1 | £15k |
| WSH FOUNDATION | 1 | £8k |
| THE CHARLES AND ELSIE SYKES TRUST | 1 | £5k |
Charities like this
- DEBRA
- CURE LEUKAEMIA
- THE SKIN CANCER RESEARCH FUND
- BRITISH SOCIETY OF ENDOVASCULAR THERAPY
- SOLEBAY CARE FUND
- FIGHT AGAINST BLINDNESS - FAB
Side by side with its peers
| Charity | Income | Top pay band | Staff >£60k | Reserves vs policy | Fundraising cost | Going concern |
|---|---|---|---|---|---|---|
| CURE EB (FORMERLY KNOWN AS SOHANA RESEARCH FUND) | £3.5m | — | 0 | unclear | — | no doubt |
| DEBRA | £17.6m | £140,001 - £150,000 | — | unclear | — | no doubt |
| CURE LEUKAEMIA | £3.7m | — | — | unclear | — | no doubt |
| THE SKIN CANCER RESEARCH FUND | £39k | — | 0 | unclear | 24.8% | no doubt |
| BRITISH SOCIETY OF ENDOVASCULAR THERAPY | £364k | — | 0 | above | — | no doubt |
| SOLEBAY CARE FUND | £91k | — | 0 | unclear | — | no doubt |